Patient characteristics
| Characteristic . | MUD vs MMUD . | P value . | TotalHvG matching . | P value . | αHvG matching . | P value . | |||
|---|---|---|---|---|---|---|---|---|---|
| MUD, n = 157 . | MMUD, n = 70 . | Mismatched, n = 57 . | Matched, n = 13 . | Mismatched, n = 49 . | Matched, n = 21 . | ||||
| Diagnosis | .087 | .24 | .31 | ||||||
| Hematological (pre)malignancy | 67 (43%) | 38 (54%) | 32 (56%) | 6 (46%) | 26 (53%) | 12 (57%) | |||
| Bone marrow failure | 36 (23%) | 7 (10%) | 4 (7.0%) | 3 (23%) | 3 (6.1%) | 4 (19%) | |||
| Hemoglobinopathy | 23 (15%) | 13 (19%) | 12 (21%) | 1 (7.7%) | 11 (22%) | 2 (9.5%) | |||
| Inborn errors of immunity | 31 (20%) | 12 (17%) | 9 (16%) | 3 (23%) | 9 (18%) | 3 (14%) | |||
| Patient age, y | 7.8 (2.6-13.3) | 9.8 (3.4-14.1) | .27 | 8.6 (3.1-13.7) | 13.1 (7.2-14.1) | 0.19 | 8.6 (2.6-13.3) | 12.7 (3.7-14.1) | .20 |
| Year of transplantation | .062 | 1 | .60 | ||||||
| 2005-2011 | 66 (42%) | 39 (56%) | 32 (56%) | 7 (54%) | 26 (53%) | 13 (62%) | |||
| 2012-2021 | 91 (58%) | 31 (44%) | 25 (44%) | 6 (46%) | 23 (47%) | 8 (38%) | |||
| Donor age (cord excluded) | 30 (24-39) | 37 (28-47) | .00022 | 40 (28-47) | 32 (24-45) | .11 | 40 (28-46) | 34 (25-47) | .46 |
| Conditioning strategy | .58 | .31 | .36 | ||||||
| Myeloablative conditioning | 147 (94%) | 64 (91%) | 53 (93%) | 11 (85%) | 46 (94%) | 18 (86%) | |||
| Reduced intensity conditioning | 10 (6.4%) | 6 (8.6%) | 4 (7.0%) | 2 (15%) | 3 (6.1%) | 3 (14%) | |||
| Stem cell source | .0030 | .32 | 1 | ||||||
| BM | 140 (89%) | 51 (73%) | 43 (75%) | 8 (62%) | 36 (73%) | 15 (71%) | |||
| PBSC | 17 (11%) | 19 (27%) | 14 (25%) | 5 (38%) | 13 (27%) | 6 (29%) | |||
| CMV status (patient/donor) | .29 | .44 | .29 | ||||||
| –/– | 57 (37%) | 18 (26%) | 16 (28%) | 2 (15%) | 13 (27%) | 5 (24%) | |||
| –/+ | 19 (12%) | 13 (19%) | 9 (16%) | 4 (31%) | 8 (16%) | 5 (24%) | |||
| +/− | 28 (18%) | 16 (23%) | 12 (21%) | 4 (31%) | 9 (18%) | 7 (33%) | |||
| +/+ | 52 (33%) | 23 (33%) | 20 (35%) | 3 (23%) | 19 (39%) | 4 (19%) | |||
| Unknown | 1 | 0 | |||||||
| Graft manipulation | .0025 | .23 | .63 | ||||||
| Alemtuzumab ex vivo | 0 (0%) | 5 (7.1%) | 3 (5.3%) | 2 (15%) | 3 (6.1%) | 2 (9.5%) | |||
| None | 157 (100%) | 65 (93%) | 54 (95%) | 11 (85%) | 46 (94%) | 19 (90%) | |||
| Characteristic . | MUD vs MMUD . | P value . | TotalHvG matching . | P value . | αHvG matching . | P value . | |||
|---|---|---|---|---|---|---|---|---|---|
| MUD, n = 157 . | MMUD, n = 70 . | Mismatched, n = 57 . | Matched, n = 13 . | Mismatched, n = 49 . | Matched, n = 21 . | ||||
| Diagnosis | .087 | .24 | .31 | ||||||
| Hematological (pre)malignancy | 67 (43%) | 38 (54%) | 32 (56%) | 6 (46%) | 26 (53%) | 12 (57%) | |||
| Bone marrow failure | 36 (23%) | 7 (10%) | 4 (7.0%) | 3 (23%) | 3 (6.1%) | 4 (19%) | |||
| Hemoglobinopathy | 23 (15%) | 13 (19%) | 12 (21%) | 1 (7.7%) | 11 (22%) | 2 (9.5%) | |||
| Inborn errors of immunity | 31 (20%) | 12 (17%) | 9 (16%) | 3 (23%) | 9 (18%) | 3 (14%) | |||
| Patient age, y | 7.8 (2.6-13.3) | 9.8 (3.4-14.1) | .27 | 8.6 (3.1-13.7) | 13.1 (7.2-14.1) | 0.19 | 8.6 (2.6-13.3) | 12.7 (3.7-14.1) | .20 |
| Year of transplantation | .062 | 1 | .60 | ||||||
| 2005-2011 | 66 (42%) | 39 (56%) | 32 (56%) | 7 (54%) | 26 (53%) | 13 (62%) | |||
| 2012-2021 | 91 (58%) | 31 (44%) | 25 (44%) | 6 (46%) | 23 (47%) | 8 (38%) | |||
| Donor age (cord excluded) | 30 (24-39) | 37 (28-47) | .00022 | 40 (28-47) | 32 (24-45) | .11 | 40 (28-46) | 34 (25-47) | .46 |
| Conditioning strategy | .58 | .31 | .36 | ||||||
| Myeloablative conditioning | 147 (94%) | 64 (91%) | 53 (93%) | 11 (85%) | 46 (94%) | 18 (86%) | |||
| Reduced intensity conditioning | 10 (6.4%) | 6 (8.6%) | 4 (7.0%) | 2 (15%) | 3 (6.1%) | 3 (14%) | |||
| Stem cell source | .0030 | .32 | 1 | ||||||
| BM | 140 (89%) | 51 (73%) | 43 (75%) | 8 (62%) | 36 (73%) | 15 (71%) | |||
| PBSC | 17 (11%) | 19 (27%) | 14 (25%) | 5 (38%) | 13 (27%) | 6 (29%) | |||
| CMV status (patient/donor) | .29 | .44 | .29 | ||||||
| –/– | 57 (37%) | 18 (26%) | 16 (28%) | 2 (15%) | 13 (27%) | 5 (24%) | |||
| –/+ | 19 (12%) | 13 (19%) | 9 (16%) | 4 (31%) | 8 (16%) | 5 (24%) | |||
| +/− | 28 (18%) | 16 (23%) | 12 (21%) | 4 (31%) | 9 (18%) | 7 (33%) | |||
| +/+ | 52 (33%) | 23 (33%) | 20 (35%) | 3 (23%) | 19 (39%) | 4 (19%) | |||
| Unknown | 1 | 0 | |||||||
| Graft manipulation | .0025 | .23 | .63 | ||||||
| Alemtuzumab ex vivo | 0 (0%) | 5 (7.1%) | 3 (5.3%) | 2 (15%) | 3 (6.1%) | 2 (9.5%) | |||
| None | 157 (100%) | 65 (93%) | 54 (95%) | 11 (85%) | 46 (94%) | 19 (90%) | |||
The data presented as n (%), with median (interquartile range) and used Fisher exact test for categorical data and Wilcoxon rank sum test for continuous data.
BM, bone marrow; CMV, cytomegalovirus; PBSC, peripheral blood stem cell.